

Media Coverage

Express Pharma, National - 16th - 31st Dec. 2009

Australian patent for Troikaa's Diclofenac injection

Troikaa Pharmaceuticals, a fast-growing healthcare company, has been granted patent in Australia for its novel drug delivery form of Diclofenac injections - Dynapar AQ, the world's first painless painkiller injection.

The company sought global protection for its novel product by filing a PCT (Patent Cooperation Treaty) application with the World Intellectual Property Organisation. Subsequently, the company filed for global patents in 99 countries, which included regulated as well as non-regulated countries.

Diclofenac injections are used for management of painful inflammatory conditions. Dynapar AQ is a unique high concentration, low viscosity injection of diclofenac sodium delivering the full therapeutic dose of diclofenac in just one millilitre injection volume. It is the only diclofenac injection available in PFS (pre-filled syringe) form.

Speaking about the patent approval, Ketan Patel, Managing Director, Troikaa Pharmaceuticals, said: " The Australia n patent is the first one granted among regulated countries. We are also expecting patent approvals in the United States, EU and Canada within the next few weeks. The company has spent about Rs. 3 crores on this endeavour but will reap manifold dividends in return.

The patent describes the novel clinical advantages of Dynapar AQ over conventional diclofenac injections. Dynapar AQ causes negligible pain and can be injected in the buttocks. This also prevents the embarrassment some patients feel on being injected in the buttocks. More importantly Dynapar AQ produces higher blood levels as compared to conventional diclofenac injection, thereby providing superior anti-inflammatory action.
